By P Reed Maurer
Foreign pharma firms operating in Japan face a recurring dilemma simply stated: Who should be our company president? What makes this decision different from any other country organization? Long-time Japan pharma watcher and president of International Alliances Limited P Reed Maurer, in his exclusive column for The Pharma Letter, says that, rather than hiding behind the knee jerk answer that says, “Because Japan is different,” let’s take an objective look at the issues.
The Japan Challenge
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze